Global Biosimilars Market Competitive Landscape, Capital


Biosimilars market

The global biosimilars market size is expected to grow from $15.67 billion in 2021 to $19.10 billion in 2022 at a compound annual growth rate (CAGR) of 21.8%. The market growth is mainly driven by businesses resuming operations and adapting to the new normal while recovering from the impact of COVID-19, which previously led to restrictive lockdown measures involving social distancing , remote working and closing business activities. which resulted in operational difficulties. The biosimilars market is expected to reach $42.30 billion in 2026 at a CAGR of 22%.

The trade research company offers the Global Biosimilars Market Report 2022 in its Research Reports Store. This is the most comprehensive report available on this market and will help you gain a truly global perspective as it covers 60 geographies. The regional and country breakdowns section gives an analysis of the market in each geography and the market size by region and country. It also compares historical and forecast market growth and highlights important trends and strategies that market players may adopt.

Buy the report directly here:

The biosimilars market consists of the sale of biosimilars and related services used to treat chronic diseases such as diabetes, arthritis and cancer. Biosimilars are pharmaceutical products made from cell lines that offer no clinical difference compared to biologics. Biosimilars are manufactured after the biologics patent has expired.

Some key players in the biosimilars market are Pfizer, Amgen, Biocon, Celltrion, Dr. Reddy’s Laboratories, Boehringer Ingelheim, Elli Lilly and Company, Mylan NV, Sanofi, STADA Arzneimittel, Sandoz International, Samsung Bioepis, Teva Pharmaceuticals, Apotex, AMEGA Biotech SA, Bioton SA, Innovent Biologics International, Allergan plc, BioXpress Therapeutics, 3SBio, Intas Biopharmaceuticals, Lupine Merck, Novartis, Ratiopharm, Wockhardt, Zydus Cadila, Allergan Plc., Hospira International., Actavis International., Johnson & Johnson and Roche.

The countries covered in the global biosimilars market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt , Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel. , Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, United Arab Emirates, United Kingdom, United States, Venezuela, Vietnam.

Regions covered in Global Biosimilars Market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Biosimilars Market Segmentation:
1) By Product:
Recombinant non-glycosylated proteins
Recombinant glycosylated proteins

2) By type:
human growth hormone
Monoclonal antibodies
Granulocyte Colony Stimulating Factor

3) Per application:
Chronic and autoimmune diseases
Growth hormone deficiency
Infectious diseases

See more about the report at

The table of contents of the report includes
1. Summary
2. Characteristics of the biosimilars market
3. Biosimilars Market Trends and Strategies
4. Impact of COVID-19 on biosimilars
5. Biosimilars Market Size and Growth
26. African Biosimilars Market
27. Biosimilars Market Competitive Landscape and Company Profiles
28. Biosimilars Pipeline Analysis
29. Major mergers and acquisitions in the biosimilars market
30. Biosimilars Market Future Outlook and Potential Analysis
31. Appendix

This report covers market trends and dynamics of the biosimilars market in major countries – Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The report also includes consumer surveys and various future opportunities for the market.

Request a sample of this report:

Contact information:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293

Check out our blog:
And follow us on:

About Us:
The Business Research Company ( is a business information company that excels in business, market and consumer research. She has published over 3,000 industry reports, covering over 2,500 market segments and 60 geographies. The reports are based on 150,000 datasets, extensive secondary research and proprietary insights from interviews with industry leaders. Reports are updated with a detailed analysis of the impact of COVID-19 on various markets.

This press release was published on openPR.

Source link


About Author

Comments are closed.